Evolution of heparin anticoagulants to ultra-low-molecular-weight heparins: A review of pharmacologic and clinical differences and applications in patients with cancer
Authors:
- Jeanine M. WalengaJWJeanine M. Walenga
- Gary H. LymanGLGary H. Lyman
- 1 October 2013
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 88 (1) , 1-18
Abstract
No abstract availableKeywords
This publication has 75 references indexed in Scilit:
- Venous Thromboembolism Prophylaxis and Treatment in Cancer: A Consensus Statement of Major Guidelines Panels and Call to ActionJournal of Clinical Oncology, 2009
- Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patientsCancer, 2007
- Incidence of Venous Thromboembolism and Its Effect on Survival Among Patients With Common CancersArchives of internal medicine (1960), 2006
- Incidence of venous thrombosis in a large cohort of 66 329 cancer patients: results of a record linkage studyJournal of Thrombosis and Haemostasis, 2006
- Incidence of Venous Thromboembolism in Patients Hospitalized with CancerThe American Journal of Medicine, 2006
- Randomized Comparison of Low Molecular Weight Heparin and Coumarin Derivatives on the Survival of Patients With Cancer and Venous ThromboembolismJournal of Clinical Oncology, 2005
- A randomized clinical trial of combination chemotherapy with and without low‐molecular‐weight heparin in small cell lung cancerJournal of Thrombosis and Haemostasis, 2004
- Low Molecular Weight Heparin, Therapy With Dalteparin, and Survival in Advanced Cancer: The Fragmin Advanced Malignancy Outcome Study (FAMOUS)Journal of Clinical Oncology, 2004
- Risk Factors for Deep Vein Thrombosis and Pulmonary EmbolismArchives of internal medicine (1960), 2000
- Subcutaneous heparin treatment increases survival in small cell lung cancerCancer, 1994